Vincerx Pharma, Inc. VINC
At closeFeb 5, 2026, 4:00 PM EST
After hours · Feb 5, 4:00 PM ET
- YTD
- 0.00%
- 1 year
- -75.00%
- Market cap
- 68.05K
- EPS (ttm)
- -9.05
- Shares out
- 33.65M
- Forward P/E
- -0.30
- YTD return
- 0.00%
- 1-year return
- -75.00%
- Volume
- 22
- Avg volume
- 712
- Open
- 0.0053
- Previous close
- 0.013
- Day's range
- 0.0053 – 0.0053
- 52-week range
- 0.005 – 0.026
- Price target
- 6.00 (+46053.8%)
- Earnings date
- Aug 8, 2024
2Y -7.1450 (-99.79%)
Key statistics
- Enterprise value
- -1.50M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.47
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -19.56M
- Total cash
- 10.09M
- Total debt
- 1.64M
- Return on equity
- -211.86%
- Short % of float
- 2.47%
- 50-day average
- 0.29914
- 200-day average
- 1.16
Analyst view
- Target (low)
- 2.00
- Target (mean)
- 6.00
- Target (high)
- 10.00
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.17 | -0.17 | 0.00 | 0.00% |
| Aug 8, 2024 | Jun 1, 2024 | -0.17 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -0.17 | -0.05 | +0.12 | +70.59% |
| May 14, 2024 | Mar 1, 2024 | -0.26 | -0.34 | -0.08 | -30.77% |
| May 14, 2024 | Mar 1, 2024 | -0.26 | — | — | — |
| Mar 29, 2024 | Dec 1, 2023 | -0.42 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 8, 2024 | Leerink Partners | main | Outperform | Outperform |
| Apr 9, 2024 | Cantor Fitzgerald | reit | — | Overweight |
| Apr 1, 2024 | Cantor Fitzgerald | reit | — | Overweight |
| Sep 7, 2023 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Nov 17, 2022 | Chardan Capital | main | — | Buy |
| Aug 12, 2022 | SVB Leerink | main | — | Outperform |
About Vincerx Pharma, Inc.
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. The company is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors. Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 and is based in Palo Alto, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- vincerx.com
News
Contrasting Whitehawk Therapeutics (NASDAQ:WHWK) & Vincerx Pharma (NASDAQ:VINC) 
Head to Head Comparison: Ampio Pharmaceuticals (NYSE:AMPE) & Vincerx Pharma (NASDAQ:VINC) 
Contrasting Vincerx Pharma (NASDAQ:VINC) and iBio (NYSE:IBIO) 
Reviewing Leap Therapeutics (NASDAQ:LPTX) and Vincerx Pharma (NASDAQ:VINC) 
Evelo Biosciences (NASDAQ:EVLO) vs. Vincerx Pharma (NASDAQ:VINC) Financial Analysis 
Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders to Vote FOR Approval of Dissolution Proposal 
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders 
Vincerx Pharma, Inc. Announces Adjournment of Special Meeting - Will Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution Proposal 
12 Health Care Stocks Moving In Tuesday's After-Market Session 
12 Health Care Stocks Moving In Tuesday's Intraday Session
Your note
Sign in to keep a note on VINC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HAMDY AHMED | President | Purchase | Aug 9, 2023 | 0 |
| IZUMI RAQUEL E. | President | Purchase | Aug 9, 2023 | 0 |
| SEELENBERGER ALEXANDER A. | Officer | Purchase | Aug 10, 2023 | 30,280 |
| THOMAS TOM C | President | Purchase | Aug 9, 2023 | 229,935 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 8.04% | 2,704,000 | 534.85K | Sep 29, 2024 |
| Prosight Management, Lp | 6.56% | 2,206,505 | 436.45K | Sep 29, 2024 |
| Sage Rhino Capital LLC | 5.06% | 1,703,413 | 336.94K | Sep 29, 2024 |
| Rock Springs Capital Management, LP | 2.65% | 891,719 | 176.38K | Sep 29, 2024 |
| Point72 Asset Management, L.P. | 2.00% | 674,193 | 133.35K | Sep 29, 2024 |
| Goldman Sachs Group Inc | 1.88% | 631,424 | 124.89K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.01% | 341,070 | 67.46K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.83% | 280,416 | 55.47K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.43% | 145,814 | 28.84K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.10% | 34,436 | 6.81K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.09% | 30,971 | 6.13K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.01% | 2,662 | 526 | Oct 30, 2024 |